View Older Stories View More Recent Stories

Apr 28, 2022 04:02PM I-Mab Biopharma (IMAB) Appoints Richard Yeh as COO and John Hayslip as Chief Medical Officer
Apr 28, 2022 04:01PM I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
Mar 31, 2022 08:02AM I-Mab Biopharma (IMAB) Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
Mar 31, 2022 08:00AM I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
Mar 29, 2022 06:12AM I-Mab Biopharma (IMAB) Reports FY21 Results, Provides Business and Corporate Updates
Mar 29, 2022 06:10AM I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
Mar 18, 2022 08:00AM I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
Mar 15, 2022 08:04AM I-Mab Biopharma (IMAB) Issues Updates Regarding Holding Foreign Companies Accountable Act
Mar 15, 2022 08:00AM I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
Mar 9, 2022 08:00AM I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 3, 2022 08:01AM I-Mab Biopharma (IMAB) Granted FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B
Mar 3, 2022 08:00AM I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
Feb 2, 2022 07:43AM AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
Jan 28, 2022 08:08AM I-Mab Biopharma (IMAB) Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
Jan 28, 2022 08:00AM I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
Jan 18, 2022 08:00AM I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
Jan 14, 2022 08:02AM I-Mab Biopharma (IMAB) Announces $2.6M of Insider Buys by Senior Management
Jan 14, 2022 08:00AM I-Mab Announces Execution of Senior Management Team Share Purchase Plan
Jan 12, 2022 08:00AM I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
Jan 6, 2022 08:01AM I-Mab Biopharma (IMAB) Management to Purchase Up to $20M Worth of Shares
Jan 6, 2022 08:00AM I-Mab Announces Senior Management Team Share Purchase Plan
Dec 31, 2021 08:00AM I-Mab Announces Upcoming Participation at January Conferences
Dec 27, 2021 08:03AM I-Mab Biopharma (IMAB) Announces IND Approval from China NMPA for Phase 2 Trial of Enoblituzumab
Dec 27, 2021 08:00AM I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Dec 20, 2021 08:00AM I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization
Dec 15, 2021 08:07AM I-Mab Biopharma (IMAB) Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
Dec 15, 2021 08:00AM I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
Dec 14, 2021 06:05AM I-Mab Biopharma (IMAB) Reports Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma
Dec 14, 2021 06:00AM I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021
Dec 9, 2021 08:00AM I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma
Dec 8, 2021 08:00AM I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
Dec 7, 2021 08:08AM I-Mab Biopharma (IMAB) to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
Dec 7, 2021 08:00AM I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
Dec 3, 2021 08:00AM I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
Nov 10, 2021 05:32AM I-Mab Biopharma (IMAB) Announces Strategic Commercial Partnership on Eftansomatropin Alfa with Jumpcan
Nov 10, 2021 04:30AM I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
Nov 9, 2021 08:06AM I-Mab Biopharma (IMAB) and ABL Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies
Nov 9, 2021 08:05AM I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
Nov 8, 2021 08:00AM I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE
Nov 4, 2021 09:05AM AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
Nov 4, 2021 09:00AM I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021
Nov 3, 2021 08:00AM I-Mab Announces Upcoming Participation at November Conferences
Nov 1, 2021 08:13AM I-Mab Biopharma (IMAB) Announces New Chief Financial Officer and Chief Strategy Officer Appointments
Nov 1, 2021 08:00AM I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments
Oct 26, 2021 08:00AM I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China
Oct 22, 2021 08:00AM I-Mab Expands U.S. Footprint with New R&D Site in San Diego
Oct 18, 2021 08:03AM I-Mab Biopharma (IMAB) Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Oct 18, 2021 08:00AM I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Oct 13, 2021 08:00AM I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China
Oct 5, 2021 08:00AM I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
View More Recent Stories View Older Stories